Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04077866CT.gov B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | — | Unknown | — | — | — |
NCT04385173CT.gov Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Egfr/B7H3 Car-T (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | P1/2 | CCC · 50 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Egfr/B7H3 Car-T
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Neuroendocrine Carcinoma | — | P1 | CC · 43 |
| Lung Cancer | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Egfr/B7H3 Car-T in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/egfrb7h3-car-t-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →